- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Anne Barmettler Discusses Potential Adverse Events Associated With Teprotumumab
Anne Barmettler, MD, an associate professor of ophthalmology, visual sciences, and plastic surgery at Montefiore Medical Center, outlines adverse events patients taking teprotumumab for thyroid eye disease may experience.
Women who are pregnant absolutely should not be on teprotumumab, said Anne Barmettler, MD, an associate professor of ophthalmology, visual sciences, and plastic surgery at Montefiore Medical Center.
Transcript
Has research been conducted on adverse events associated with teprotumumab since it has become available on the market?
Yes. Actually, even in the original studies, there were some additional side effects that patients should be aware of, and physicians. Some patients may experience hearing changes; this is often described as feeling like the patient is underwater. Some patients even feel that they lose hearing. And although some of that is reversible—that is, when the patient stops taking the medication, their hearing comes back—sometimes it is not reversible.
Another big thing to think about is that in patients with preexisting diabetes or other issues with higher blood glucose, this can cause the blood glucose to elevate dramatically. This has to be monitored carefully, because that can cause issues requiring even hospitalization.
One final thing is that teprotumumab is an insulin growth factor receptor antibody. This is really crucial in development. So women who are pregnant absolutely cannot be on this medication, as this would be very damaging. That's certainly something to think about as a lot of women who have thyroid eye disease are of childbearing age.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Following Roe v Wade Overturn, Research Focuses on Male Contraceptives
May 6th 2024Stephanie T. Page, MD, PhD, UW Medicine Diabetes Institute, presented on ongoing research and growing interest in new male contraceptive options, such as an oral pill and a hormonal transdermal gel, at the American Urological Association 2024 Annual Meeting.
Read More
